Render Target: SSR
Render Timestamp:
3/27/2025, 2:11:12 PM EDT
3/27/2025, 6:11:12 PM UTC
Commit: 461ca8d8fe5b1efd4c01fc87e5b5eb592e2d154a
XML generation date: 2025-03-07 13:20:25.344
Product last modified at: 2025-03-10T20:15:10.945Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

Eosinophil peroxidase (F4O7J) Rabbit mAb #31743

Filter:
  • WB
  • IHC

    Supporting Data

    REACTIVITY H M
    SENSITIVITY Endogenous
    MW (kDa) 81, 45-50, 20-25
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunohistochemistry (Paraffin) 1:500 - 1:2000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Eosinophil peroxidase (F4O7J) Rabbit mAb recognizes endogenous levels of total Eosinophil peroxidase protein. This antibody recognizes the full-length precursor, heavy chain, and light chain subunits of human Eosinophil peroxidase protein. This antibody is not recommended for immunohistochemical analysis of mouse tissues.

    Species Reactivity:

    Human, Mouse

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asn585 of human Eosinophil peroxidase protein.

    Background

    Eosinophil peroxidase (EPX), also known as EPO, is a cationic protein stored in the secondary granulocytes of eosinophils (1-4). Unprocessed precursor EPX is an 80 kDa monomeric glycoprotein, which consists of two polypeptides linked by disulfide bonds: ~55 kDa heavy and ~15 kDa light chain (1-3, 6). In response to allergens or parasitic infection, eosinophils are recruited to affected tissues, where EPX catalyzes the formation of reactive oxidants lethal to tissue-invading parasites (1-4). In the tumor microenvironment of some breast cancers, eosinophils accumulate near blood vessels and infiltrate hypoxic regions, where EPX is released in high quantities by infiltrating immune cells (5). EPX may contribute to cancer progression by augmenting pro-tumorigenic collagen production and angiogenesis, making it a potential therapeutic target in breast cancer therapy (5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.